Delivering scheduled and unscheduled therapy without detriment to battery life or accuracy of longevity predictions
-
0Associated
Cases -
0Associated
Defendants -
0Accused
Products -
0Forward
Citations -
0
Petitions -
1
Assignment
First Claim
1. A method comprising:
- applying an electrical signal of electrical signals of scheduled stimulation to a neural structure via an implantable medical device (IMD), wherein the scheduled stimulation is defined by a plurality of parameters and characterized by a first rate of electrical charge delivery to the neural structure, and wherein the first rate is based on one or more of the plurality of parameters;
detecting an event at the IMD after application of the electrical signal and before application of a next scheduled electrical signal of the scheduled stimulation;
applying event stimulation to the neural structure via the IMD in response to detection of the event;
adjusting at least one parameter of the plurality of parameters that define the scheduled stimulation in response to detection of the event to define adjusted stimulation characterized by a second rate of electrical charge delivery to the neural structure that is less than the first rate;
applying the adjusted stimulation to the neural structure via the IMD after application of the event stimulation to compensate for electrical charge delivery due to the event stimulation; and
applying at least one electrical signal of the scheduled stimulation to the neural structure via the IMD after application of the adjusted stimulation.
1 Assignment
0 Petitions

Accused Products

Abstract
A method comprises applying a first open-loop electrical signal to a neural structure at a first rate. The method also comprises applying a closed-loop electrical signal to the neural structure in response to an event detection, thus causing an overall rate at which electrical stimulation is applied to the neural structure to exceed the first rate. The method further comprises applying a second open-loop electrical signal to a neural structure at a second rate that is lower than the first rate, thus causing the overall rate to be reduced to the first rate.
119 Citations
No References
Lead adaptor having low resistance conductors and/or encapsulated housing | ||
Patent #
US 7,904,161 B2
Filed 07/12/2005
|
Current Assignee
Oscor Inc
|
Sponsoring Entity
Oscor Inc
|
Power supply monitoring for an implantable device | ||
Patent #
US 7,751,891 B2
Filed 07/28/2004
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
METHOD AND APPARATUS THAT DETECTS STATE OF CHARGE (SOC) OF A BATTERY | ||
Patent #
US 20100121591A1
Filed 11/11/2009
|
Current Assignee
Leidos Innovations Technology Inc.
|
Sponsoring Entity
Leidos Innovations Technology Inc.
|
Method and system for energy conservation in implantable stimulation devices | ||
Patent #
US 7,584,000 B2
Filed 05/12/2006
|
Current Assignee
Advanced Neuromodulation Systems Incorporated
|
Sponsoring Entity
Advanced Neuromodulation Systems Incorporated
|
DYNAMIC BATTERY MANAGEMENT IN AN IMPLANTABLE DEVICE | ||
Patent #
US 20080097544A1
Filed 10/20/2006
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
-
|
Electrical stimulation strategies to reduce the incidence of seizures | ||
Patent #
US 7,174,213 B2
Filed 09/11/2001
|
Current Assignee
Neuropace Inc.
|
Sponsoring Entity
Neuropace Inc.
|
IMPLANTABLE MEDICAL DEVICE POWERED BY RECHARGEABLE BATTERY | ||
Patent #
US 20070150019A1
Filed 12/14/2006
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Electrical nerve stimulation device | ||
Patent #
US 7,254,444 B2
Filed 10/17/2002
|
Current Assignee
Encore Medical Asset Corporation
|
Sponsoring Entity
Encore Medical Asset Corporation
|
Method for judging service life of primary battery | ||
Patent #
US 20070216366A1
Filed 03/13/2007
|
Current Assignee
Sanyo Electric Company Limited
|
Sponsoring Entity
Sanyo Electric Company Limited
|
Compensation reduction in tissue stimulation therapy | ||
Patent #
US 20070255374A1
Filed 04/28/2006
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Implantable neurostimulator programming with battery longevity indication | ||
Patent #
US 7,142,923 B2
Filed 10/29/2003
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Battery charge indicator such as for an implantable medical device | ||
Patent #
US 20050088145A1
Filed 10/23/2003
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
System and method for monitoring power source longevity of an implantable medical device | ||
Patent #
US 6,901,293 B2
Filed 04/07/2003
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Implantable neurostimulator programming with battery longevity indication | ||
Patent #
US 20050177206A1
Filed 10/29/2003
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Battery charge indicator such as for an implantable medical device | ||
Patent #
US 6,940,255 B2
Filed 10/23/2003
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Lead adaptor having low resistance conductors and/or encapsulated housing | ||
Patent #
US 20050272280A1
Filed 07/12/2005
|
Current Assignee
Oscor Inc
|
Sponsoring Entity
Oscor Inc
|
Trial neuro stimulator with lead diagnostics | ||
Patent #
US 6,687,538 B1
Filed 06/19/2000
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
System and method for determining remaining battery life for an implantable medical device | ||
Patent #
US 20040039424A1
Filed 08/28/2003
|
Current Assignee
Merritt Donald R., Crandall Kathleen U., Kleckner Karen J., Mukul Jain, Busacker James W.
|
Sponsoring Entity
Merritt Donald R., Crandall Kathleen U., Kleckner Karen J., Mukul Jain, Busacker James W.
|
Implantable lead functional status monitor and method | ||
Patent #
US 6,721,600 B2
Filed 12/31/2001
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Electronic impedance transformer for inductively-coupled load stabilization | ||
Patent #
US 6,745,077 B1
Filed 10/09/2001
|
Current Assignee
Advanced Bionics
|
Sponsoring Entity
Advanced Bionics Corporation
|
Method and circuit for determining the battery status in a medical implant | ||
Patent #
US 6,748,273 B1
Filed 06/03/2002
|
Current Assignee
St. Jude Medical AB
|
Sponsoring Entity
St. Jude Medical AB
|
Method and apparatus for measuring lead impedance in an implantable cardiac rhythm management device | ||
Patent #
US 6,760,624 B2
Filed 12/03/2001
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Battery monitoring system for an implantable medical device | ||
Patent #
US 6,760,625 B1
Filed 11/21/2001
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Battery monitoring system for an implantable medical device | ||
Patent #
US 6,804,557 B1
Filed 10/11/2001
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
System and method for monitoring power source longevity of an implantable medical device | ||
Patent #
US 20040199146A1
Filed 04/07/2003
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Device and method for determining and communicating the remaining life of a battery in an implantable neurological tissue stimulating device | ||
Patent #
US 6,820,019 B1
Filed 07/31/1999
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Implantable pulse generators using rechargeable zero-volt technology lithium-ion batteries | ||
Patent #
US 6,553,263 B1
Filed 07/28/2000
|
Current Assignee
Boston Scientific Neuromodulation Corporation
|
Sponsoring Entity
Quallion LLC, Advanced Bionics Corporation
|
Electrical nerve stimulation device | ||
Patent #
US 20030074037A1
Filed 10/17/2002
|
Current Assignee
Encore Medical Asset Corporation
|
Sponsoring Entity
Encore Medical Asset Corporation
|
Vagal nerve stimulation techniques for treatment of epileptic seizures | ||
Patent #
US 6,587,727 B2
Filed 11/09/2001
|
Current Assignee
Ivan Osorio, Mark G. Frei
|
Sponsoring Entity
Ivan Osorio, Mark G. Frei
|
Treatment of obesity by bilateral vagus nerve stimulation | ||
Patent #
US 6,587,719 B1
Filed 07/01/1999
|
Current Assignee
CYBERRONICS INC.
|
Sponsoring Entity
CYBERRONICS INC.
|
Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation | ||
Patent #
US 6,609,025 B2
Filed 01/02/2001
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of congestive heart failure and autonomic cardiovascular drive disorders | ||
Patent #
US 6,622,041 B2
Filed 08/21/2001
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of movement disorders by near-diaphragmatic nerve stimulation | ||
Patent #
US 6,622,038 B2
Filed 07/28/2001
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Method and system for medical lead impedance test | ||
Patent #
US 6,620,186 B2
Filed 05/10/2001
|
Current Assignee
International Business Machines Corporation
|
Sponsoring Entity
International Business Machines Corporation
|
Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation | ||
Patent #
US 6,622,047 B2
Filed 07/28/2001
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Method for monitoring end of life for battery | ||
Patent #
US 6,631,293 B2
Filed 04/23/2001
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Method and system of follow-up support for a medical device | ||
Patent #
US 6,648,823 B2
Filed 07/31/2001
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Method for monitoring end of life for battery | ||
Patent #
US 6,654,640 B2
Filed 03/06/2002
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
System and method for determining remaining battery life for an implantable medical device | ||
Patent #
US 6,671,552 B2
Filed 10/02/2001
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Multichannel stimulator electronics and methods | ||
Patent #
US 6,662,053 B2
Filed 04/19/2001
|
Current Assignee
William N. Borkan
|
Sponsoring Entity
William N. Borkan
|
Vagal nerve stimulation techniques for treatment of epileptic seizures | ||
Patent #
US 6,671,556 B2
Filed 11/09/2001
|
Current Assignee
Ivan Osorio, Mark G. Frei
|
Sponsoring Entity
Ivan Osorio, Mark G. Frei
|
Implantable cardiac device having an impedance monitoring circuit and method | ||
Patent #
US 6,658,294 B1
Filed 08/29/2001
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Vagal nerve stimulation techniques for treatment of epileptic seizures | ||
Patent #
US 6,341,236 B1
Filed 04/30/1999
|
Current Assignee
Flint Hills Scientific LLC
|
Sponsoring Entity
Ivan Osorio, Mark G. Frei
|
Multichannel stimulator electronics and methods | ||
Patent #
US 20020022866A1
Filed 04/19/2001
|
Current Assignee
William N. Borkan
|
Sponsoring Entity
William N. Borkan
|
Implantable cardiac device having precision RRT indication | ||
Patent #
US 6,400,988 B1
Filed 02/18/2000
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Power management for an implantable medical device | ||
Patent #
US 6,453,198 B1
Filed 04/28/2000
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Implantable cardiac stimulating device incorporating high frequency low amplitude lead impedance measurement | ||
Patent #
US 6,445,951 B1
Filed 10/12/1999
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Method to enhance cardiac capillary growth in heart failure patients | ||
Patent #
US 6,473,644 B1
Filed 10/13/1999
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Apparatus and method for estimating battery condition in implantable cardioverter/defibrillators | ||
Patent #
US 6,490,484 B2
Filed 01/24/2001
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Implantable cardiac stimulation device and method that monitors displacement of an implanted lead | ||
Patent #
US 6,490,486 B1
Filed 11/09/2000
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Programmable current output stimulus stage for implantable device | ||
Patent #
US 6,181,969 B1
Filed 06/23/1999
|
Current Assignee
Advanced Bionics LLC
|
Sponsoring Entity
Advanced Bionics Corporation
|
System and method for verification of recommended replacement time indication in an implantable cardiac stimulation device | ||
Patent #
US 6,185,461 B1
Filed 07/01/1998
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Power transfer circuit for implanted devices | ||
Patent #
US 6,212,431 B1
Filed 08/18/1999
|
Current Assignee
Advanced Bionics
|
Sponsoring Entity
Advanced Bionics Corporation
|
Method for monitoring end of life for battery | ||
Patent #
US 20010034541A1
Filed 04/23/2001
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Implantable lead functional status monitor and method | ||
Patent #
US 6,317,633 B1
Filed 01/19/2000
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Multilevel ERI for implantable medical devices | ||
Patent #
US 6,016,448 A
Filed 10/27/1998
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Efficient integrated RF telemetry transmitter for use with implantable device | ||
Patent #
US 6,073,050 A
Filed 11/10/1998
|
Current Assignee
Advanced Bionics
|
Sponsoring Entity
Advanced Bionics Corporation
|
Battery monitoring apparatus and method for programmers of cardiac stimulating devices | ||
Patent #
US 6,108,579 A
Filed 04/11/1997
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Implantable stimulator with battery status measurement | ||
Patent #
US 6,148,235 A
Filed 07/17/1998
|
Current Assignee
VITATRON MEDICAL B.V.
|
Sponsoring Entity
VITATRON MEDICAL B.V.
|
Method for monitoring end of life for battery | ||
Patent #
US 6,167,309 A
Filed 09/15/1997
|
Current Assignee
Cardiac Pacemakers Incorporated
|
Sponsoring Entity
Cardiac Pacemakers Incorporated
|
Power control loop for implantable tissue stimulator | ||
Patent #
US 5,876,425 A
Filed 09/19/1997
|
Current Assignee
Advanced Bionics
|
Sponsoring Entity
-
|
Pacing lead impedance monitoring circuit and method | ||
Patent #
US 5,897,577 A
Filed 11/07/1997
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
-
|
Method and apparatus for monitoring and displaying lead impedance in real-time for an implantable medical device | ||
Patent #
US 5,891,179 A
Filed 11/20/1997
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity | ||
Patent #
US 5,928,272 A
Filed 05/02/1998
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
-
|
Method for determining an ICD replacment time | ||
Patent #
US 5,925,068 A
Filed 02/06/1998
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Treating refractory hypertension by nerve stimulation | ||
Patent #
US 5,707,400 A
Filed 09/19/1995
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Implantable medical device with end-of-life battery detection circuit | ||
Patent #
US 5,713,936 A
Filed 01/23/1996
|
Current Assignee
LITRONIK BATTERIETECHNOLOGIE GMBH CO
|
Sponsoring Entity
LITRONIK BATTERIETECHNOLOGIE GMBH CO
|
Implantable medical device system with method for determining lead condition | ||
Patent #
US 5,741,311 A
Filed 06/27/1996
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Method for determining an ICD replacement time | ||
Patent #
US 5,741,307 A
Filed 01/21/1997
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Cardioversion/defibrillation lead impedance measurement system | ||
Patent #
US 5,755,742 A
Filed 11/05/1996
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Meter for measuring battery charge delivered in an implantable device | ||
Patent #
US 5,769,873 A
Filed 10/15/1996
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Cardiac stimulator with lead failure detector and warning system | ||
Patent #
US 5,814,088 A
Filed 03/26/1997
|
Current Assignee
Intermedics Incorporated
|
Sponsoring Entity
Intermedics Incorporated
|
System and method for determining indicated pacemaker replacement time based upon battery impedance measurement | ||
Patent #
US 5,620,474 A
Filed 04/24/1995
|
Current Assignee
VITATRON MEDICAL B.V.
|
Sponsoring Entity
VITATRON MEDICAL B.V.
|
System for determining battery conditions | ||
Patent #
US 5,703,469 A
Filed 05/30/1996
|
Current Assignee
Honda Giken Kogyo Kabushiki Kaisha
|
Sponsoring Entity
Honda Giken Kogyo Kabushiki Kaisha
|
End-of-life indication system for implantable pulse generator | ||
Patent #
US 5,496,353 A
Filed 09/23/1993
|
Current Assignee
Gregory P. Gadson
|
Sponsoring Entity
Gregory P. Gadson
|
System and method for measuring and storing parametric data pertaining to operating characteristics of an implantable medical device | ||
Patent #
US 5,507,786 A
Filed 04/14/1994
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Voltage/current control system for a human tissue stimulator | ||
Patent #
US 5,522,865 A
Filed 10/12/1994
|
Current Assignee
Alfred E. Mann Foundation For Scientific Research
|
Sponsoring Entity
Alfred E. Mann Foundation For Scientific Research
|
Automatic lead recognition for implantable medical device | ||
Patent #
US 5,534,018 A
Filed 11/30/1994
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Treatment of motility disorders by nerve stimulation | ||
Patent #
US 5,540,730 A
Filed 06/06/1995
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Cranial nerve stimulation treatments using neurocybernetic prosthesis | ||
Patent #
US 5,540,734 A
Filed 09/28/1994
|
Current Assignee
Jacob Zabara
|
Sponsoring Entity
Jacob Zabara
|
Periodic electrical lead intergrity testing system and method for implantable cardiac stimulating devices | ||
Patent #
US 5,549,646 A
Filed 12/06/1994
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Pacesetter Incorporated
|
Treatment of patients in coma by nerve stimulation | ||
Patent #
US 5,571,150 A
Filed 12/19/1994
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Method and apparatus for battery depletion monitoring | ||
Patent #
US 5,391,193 A
Filed 02/05/1993
|
Current Assignee
Dwight N. Holmbo
|
Sponsoring Entity
Dwight N. Holmbo
|
Method and apparatus for testing compatibility of lead polarity and polarity programming of a cardiac stimulator | ||
Patent #
US 5,431,692 A
Filed 08/02/1993
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Telectronics Pacing Systems Inc
|
Cardiac pacing system with improved end-of-life detector | ||
Patent #
US 5,458,624 A
Filed 10/06/1993
|
Current Assignee
VITATRON MEDICAL B.V.
|
Sponsoring Entity
VITATRON MEDICAL B.V.
|
Treatment of neuropsychiatric disorders by nerve stimulation | ||
Patent #
US 5,299,569 A
Filed 05/03/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of pain by vagal afferent stimulation | ||
Patent #
US 5,330,515 A
Filed 06/17/1992
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Therapeutic treatment of sleep disorder by nerve stimulation | ||
Patent #
US 5,335,657 A
Filed 05/03/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Method and apparatus for determination of end-of-service for implantable devices | ||
Patent #
US 5,344,431 A
Filed 09/14/1992
|
Current Assignee
Daniel W. Latham
|
Sponsoring Entity
Daniel W. Latham
|
Brushless polyphase reduced force variation motor | ||
Patent #
US 5,352,962 A
Filed 04/19/1993
|
Current Assignee
ASML US LLC, ASML US Incorporated, ASML Holding NV
|
Sponsoring Entity
SVG Lithography Systems Incorporated
|
Battery charge state determination | ||
Patent #
US 5,352,968 A
Filed 05/28/1992
|
Current Assignee
Apple Computer Incorporated
|
Sponsoring Entity
Apple Computer Incorporated
|
Method and apparatus for monitoring pacemaker intervals | ||
Patent #
US 5,372,607 A
Filed 06/23/1993
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Implanted apparatus having micro processor controlled current and voltage sources with reduced voltage levels when not providing stimulation | ||
Patent #
US 5,179,950 A
Filed 12/05/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of eating disorders by nerve stimulation | ||
Patent #
US 5,188,104 A
Filed 02/01/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
In vivo implantable medical device with battery monitoring circuitry | ||
Patent #
US 5,193,538 A
Filed 01/09/1992
|
Current Assignee
Pacesetter AB
|
Sponsoring Entity
Siemens AG
|
Medical lead impedance measurement system | ||
Patent #
US 5,201,865 A
Filed 10/28/1991
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Minute volume rate-responsive pacemaker employing impedance sensing on a unipolar lead | ||
Patent #
US 5,201,808 A
Filed 02/10/1992
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Telectronics Pacing Systems Inc
|
Implantable tissue stimulator output stabilization system | ||
Patent #
US 5,222,494 A
Filed 07/31/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Therapeutic treatment of migraine symptoms by stimulation | ||
Patent #
US 5,215,086 A
Filed 05/03/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of endocrine disorders by nerve stimulation | ||
Patent #
US 5,231,988 A
Filed 08/09/1991
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of eating disorders by nerve stimulation | ||
Patent #
US 5,263,480 A
Filed 08/07/1992
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Treatment of dementia by nerve stimulation | ||
Patent #
US 5,269,303 A
Filed 02/22/1991
|
Current Assignee
CYBERONICS INC. WEBSTER TEXAS A CORP. OF DE
|
Sponsoring Entity
CYBERONICS INC. WEBSTER TEXAS A CORP. OF DE
|
Telemetry format for implanted medical device | ||
Patent #
US 5,127,404 A
Filed 09/25/1991
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Lead current measurement circuit | ||
Patent #
US 5,137,021 A
Filed 11/29/1990
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Battery impedance measurement apparatus | ||
Patent #
US 5,137,020 A
Filed 11/29/1990
|
Current Assignee
Medtronic Incorporated
|
Sponsoring Entity
Medtronic Incorporated
|
Wireless low-frequency medical treatment device with pulse interruption based upon electrode contact with the body | ||
Patent #
US 5,146,920 A
Filed 11/15/1990
|
Current Assignee
Sanyo Electric Company Limited
|
Sponsoring Entity
Sanyo Electric Company Limited
|
Constant current sources with programmable voltage source | ||
Patent #
US 5,154,172 A
Filed 11/13/1989
|
Current Assignee
Cyberonics Inc
|
Sponsoring Entity
Cyberonics Inc
|
Neurocybernetic prosthesis | ||
Patent #
US 5,025,807 A
Filed 01/25/1989
|
Current Assignee
Jacob Zabara
|
Sponsoring Entity
Jacob Zabara
|
Lead impedance scanning system for pacemakers | ||
Patent #
US 4,899,750 A
Filed 04/19/1988
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
SIEMENS-PACESETTER INC.
|
Method and apparatus for assuring pacer programming is compatible with the lead | ||
Patent #
US 4,964,407 A
Filed 08/29/1988
|
Current Assignee
INTERMEDICS INC. ANGLETON TX A CORP. OF TX
|
Sponsoring Entity
INTERMEDICS INC. ANGLETON TX A CORP. OF TX
|
Defibrillator electrode system | ||
Patent #
US 4,850,356 A
Filed 02/09/1988
|
Current Assignee
Kimberly-Clark Worldwide Incorporated
|
Sponsoring Entity
DAROX CORPORATION
|
Neurocybernetic prosthesis | ||
Patent #
US 4,867,164 A
Filed 10/26/1987
|
Current Assignee
Jacob Zabara
|
Sponsoring Entity
Jacob Zabara
|
Battery test circuit for a heart pacemaker | ||
Patent #
US 4,686,990 A
Filed 09/17/1986
|
Current Assignee
Pacesetter AB
|
Sponsoring Entity
Siemens AG
|
Neurocybernetic prosthesis | ||
Patent #
US 4,702,254 A
Filed 12/30/1985
|
Current Assignee
Jacob Zabara
|
Sponsoring Entity
Jacob Zabara
|
Battery test circuit for a heart pacemaker | ||
Patent #
US 4,715,381 A
Filed 09/17/1986
|
Current Assignee
Pacesetter AB
|
Sponsoring Entity
Siemens AG
|
Cardiac pacer with battery consumption monitor circuit | ||
Patent #
US 4,556,061 A
Filed 03/12/1985
|
Current Assignee
Pacesetter Incorporated
|
Sponsoring Entity
Cordis Corporation
|
Battery condition warning system for medical implant | ||
Patent #
US 4,488,555 A
Filed 12/13/1982
|
Current Assignee
Mirowski Family Ventures LLC
|
Sponsoring Entity
MIROWSKI MIECZYSLAW
|
Battery monitoring means and method for an implantable tissue stimulator | ||
Patent #
US 4,324,251 A
Filed 06/10/1980
|
Current Assignee
Pacesetter AB
|
Sponsoring Entity
Pacesetter Systems Inc.
|
APPARATUS FOR DELIVERING ELECTRICAL STIMULATION ENERGY TO BODY-IMPLANTED APPARATUS WITH SIGNAL-RECEIVING MEANS | ||
Patent #
US 3,796,221 A
Filed 07/07/1971
|
Current Assignee
Hagfors Norman R.
|
Sponsoring Entity
Hagfors Norman R.
|
20 Claims
- 1. A method comprising:
applying an electrical signal of electrical signals of scheduled stimulation to a neural structure via an implantable medical device (IMD), wherein the scheduled stimulation is defined by a plurality of parameters and characterized by a first rate of electrical charge delivery to the neural structure, and wherein the first rate is based on one or more of the plurality of parameters; detecting an event at the IMD after application of the electrical signal and before application of a next scheduled electrical signal of the scheduled stimulation; applying event stimulation to the neural structure via the IMD in response to detection of the event; adjusting at least one parameter of the plurality of parameters that define the scheduled stimulation in response to detection of the event to define adjusted stimulation characterized by a second rate of electrical charge delivery to the neural structure that is less than the first rate; applying the adjusted stimulation to the neural structure via the IMD after application of the event stimulation to compensate for electrical charge delivery due to the event stimulation; and applying at least one electrical signal of the scheduled stimulation to the neural structure via the IMD after application of the adjusted stimulation. - View Dependent Claims (2, 3, 4, 5)
- 6. A system, comprising:
detection logic adapted to detect an event; and stimulation logic coupled to the detection logic and adapted to apply scheduled stimulation, adjusted stimulation, and event stimulation to a neural structure; wherein the scheduled stimulation is characterized by a plurality of parameters and by a first rate of electrical charge delivery to the neural structure that is based on the plurality of parameters; wherein, upon receipt of notification from the detection logic of detection of the event after application of an electrical signal of the scheduled stimulation and before application of a next scheduled electrical signal of the scheduled stimulation, the stimulation logic applies event stimulation to the neural structure; wherein, upon application of the event stimulation to the neural structure, the stimulation logic adjusts one or more parameters of the plurality of parameters to define the adjusted stimulation, wherein the adjusted stimulation is characterized by a second rate of electrical charge delivery to the neural structure that is less than the first rate; and wherein application of the adjusted stimulation to the neural structure compensates for electrical charge delivery due to the event stimulation. - View Dependent Claims (7, 8, 9, 10, 11, 12)
- 13. A non-transitory computer-readable medium comprising instructions executable by a processor to:
cause an electrical signal of electrical signals of scheduled stimulation to be sent to an electrode assembly, wherein the scheduled stimulation is characterized by a first charge delivery rate; cause event stimulation to be sent to the electrode assembly in response to detection of an event after the electrical signal is sent and before a next scheduled electrical signal of the scheduled stimulation is to be sent; determine adjusted stimulation characterized by a second electrical charge delivery rate that is less than the first charge delivery rate to compensate for electrical charge delivery due to the event stimulation sent to the electrode assembly; and cause the adjusted stimulation to be sent to the electrode assembly. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20)
1 Specification
Medical treatments for disorders of the nervous system, such as seizure disorders (e.g., epilepsy), have improved in recent decades. One available treatment involves the application of an electrical signal to reduce various symptoms or effects caused by such neural disorders. For example, electrical signals have been successfully applied at strategic locations in the human body to provide various benefits, including a reduction of seizure occurrence and the improvement of other medical conditions. An example of such a treatment regimen involves the application of electrical stimulation to the vagus nerve of the human body to reduce or eliminate epileptic seizures, as described in U.S. Pat. No. 4,702,254, which is incorporated herein by reference.
Electrical stimulation of a target tissue of a patient'"'"'s body may be provided by implanting an electrical device (known as an implantable medical device, or IMD) underneath the skin of a patient and electrically stimulating the target tissue. In some cases, electrical stimulation of target tissue (including, but not limited to neural tissue such as the vagus nerve) may be delivered in accordance with a programmed (or predetermined or “planned”) schedule. In such cases, the electrical stimulation is referred to as “open-loop,” “passive,” or “non-feedback” stimulation. In other cases, electrical stimulation may be delivered in response to detecting some type of event. In one embodiment, the event may be patient-initiated. In another embodiment, the event may be detecting a change in one or more body parameters (for example, cardiac rhythm, muscle activity, or body movements). Typically, the parameter(s) is selected such that the change is indicative of a disease state such as an epileptic seizure. This type of stimulation is known as “closed-loop,” “active” or “feedback” stimulation. In some devices, both open-loop and closed-loop stimulation may be simultaneously employed, with an open-loop program operating to provide a basic level of therapy and closed-loop stimulation provided in response to episodic events.
Whether delivered as closed-loop or open-loop, the stimulation is typically applied as a sequence of pulses (collectively referred to as a “burst”) extending for a defined duration (known as the “on-time” or “burst duration”). In open-loop stimulation, the pulse bursts are separated by a programmed time period (the “off-time”), and in closed-loop stimulation the bursts are delivered in response to the detected event and may include a refractory period after the closed-loop burst to allow the nerve to recover. During the on-time of a pulse burst, electrical pulses of a defined electrical current (e.g., 0.5-3.5 milliamps) and pulse width (e.g., 0.25-1.0 milliseconds) are delivered at a defined frequency (e.g., 20-30 Hz) for the burst duration (e.g., 7-60 seconds). For open-loop stimulation, the on-time and off-time parameters together define a duty cycle, which is the ratio of the on-time to the combination of the on-time and off-time, and which describes the percentage of time that the electrical signal is applied to the nerve.
Most IMDs are powered by batteries; consequently, the amount of power available to them is finite. Just before the battery of an IMD is exhausted, the IMD must be surgically removed from a patient'"'"'s body so that a new device (or battery) may be installed. For this reason, the ability to accurately predict a battery'"'"'s remaining life is crucial to ensuring that therapy to the patient is not interrupted, which may endanger the patient'"'"'s health. Overestimating an IMD'"'"'s battery life can result in interruption of therapy by precluding timely replacement of the IMD and/or battery prior to exhaustion of its electrical charge. One the other hand, underestimating an IMD'"'"'s battery life can result in surgery that is not necessary at that time and a waste of the useful life of the IMD.
Predicting battery life generally is relatively uncomplicated when an IMD only applies electrical pulses in accordance with a planned schedule (“open-loop” stimulation). When closed-loop stimulation is used (either alone or in combination with open-loop stimulation), predicting battery life becomes difficult, because closed-loop stimulation is patient-specific and does not occur according to any predetermined schedule. Further, delivering closed-loop stimulation in addition to scheduled, open-loop stimulation may result not only in overstimulation but also may substantially reduce battery life.
Thus, methods and systems for conserving, extending and accurately predicting battery life in IMDs that apply closed-loop stimulation are desired.
For a detailed description of exemplary embodiments of the invention, reference will now be made to the accompanying drawings in which:
Certain terms are used throughout the following description and claims to refer to particular system components. As one skilled in the art will appreciate, companies may refer to a component by different names. This document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . .” Also, the term “couple” or “couples” is intended to mean either an indirect or direct electrical connection. Thus, if a first device couples to a second device, that connection may be through a direct electrical connection, or through an indirect electrical connection via other devices and connections.
The following discussion is directed to various embodiments of the invention. Although one or more of these embodiments may be preferred, the embodiments disclosed should not be interpreted, or otherwise construed, as limiting the scope of the disclosure, including the claims. In addition, one skilled in the art will understand that the following description has broad application, and the discussion of any embodiment is meant only to be exemplary of that embodiment, and not intended to intimate that the scope of the disclosure, including the claims, is limited to that embodiment.
Disclosed herein are various techniques for conserving, extending and accurately predicting battery life in an implantable medical device (IMD) that delivers both open-loop and closed-loop electrical stimulation. Techniques for conserving and extending battery life are described first, followed by a description of techniques for accurately predicting battery life.
In some battery life conservation embodiments of the present invention, the predetermined schedule at which open-loop stimulation is to be administered is dynamically adjusted to compensate for any closed-loop stimulation burst that is provided outside the predetermined open-loop schedule. For example, in some of these embodiments, a closed-loop stimulation burst may cause the open-loop stimulation schedule to be “reset” so that open-loop stimulation bursts are delivered as scheduled, but with the schedule “resynchronized” to provide subsequent open-loop bursts based upon the closed-loop stimulation burst rather than the immediately preceding open-loop burst. In some embodiments, a closed-loop stimulation burst may cause the next planned open-loop stimulation burst to be skipped, such that the closed-loop burst is “substituted” for the skipped open-loop burst. In some embodiments, a closed-loop stimulation burst may be compensated for by increasing the length of one or more off-time cycles following the closed-loop stimulation burst; similarly, in some embodiments, a closed-loop stimulation burst may be compensated for by decreasing the length of one or more scheduled stimulation bursts following the closed-loop stimulation burst. In some cases, one or more of the foregoing techniques may be combined. Various embodiments are now described in detail with reference to the figures.
The IMD 110 may be controlled or programmed with an external device 150 (e.g., a computer) and a programming wand 155 to facilitate radio frequency (RF) communication between the external device 150 and the IMD 110. The wand 155 and software permit noninvasive communication with the IMD 110 after the latter is implanted. In systems where the external device 150 uses one or more channels in the Medical Implant Communications Service (MICS) bandwidths, the programming wand 155 may be omitted to permit more convenient communication directly between the external device 150 and the IMD 110.
The power-source controller 220 preferably comprises circuitry for controlling and monitoring the flow of electrical power to various electronic and stimulation-portions of the IMD 110 (such as the components 230, 240, 250, 260 and 280 illustrated in
The communication unit 260 facilitates communication between the IMD 110 and the external unit 150, as shown. The external unit 150 may be a device that is capable of programming various components and stimulation parameters of the IMD 110. In one embodiment, the external unit 150 is a computer system capable of electronic communications, programming, and executing a data-acquisition program, preferably a handheld computer or PDA. The external unit 150 preferably is controlled by a healthcare provider such as a physician in, for example, a doctor'"'"'s office. The external unit 150 may be used to download various parameters and program software into the IMD 110 for programming the operation of the IMD. The external unit 150 may also receive and upload various status conditions and other data from the IMD 110. The communication unit 260 may comprise hardware, software, firmware or any combination thereof. Communications between the external unit 150 and the communication unit 260 may occur via a wireless or other type of communication, illustrated generally by line 275 in
The power regulation unit 240 is capable of regulating power delivered by the power source 210 to particular components of the IMD 110 according to their needs and functions. The power regulation unit 240 may perform a voltage conversion to provide appropriate voltages and/or currents for the operation of the components. The power regulation unit 240 may comprise hardware, software, firmware or any combination thereof. The communication unit 260 is capable of providing transmission and reception of electronic signals to and from an external unit 150.
Stimulation controller 230 defines the electrical stimulation pulses to be delivered as part of a burst to the nerve tissue according to parameters and waveforms that may be programmed into the IMD 110 using the external unit 150 or that may be pre-programmed into the controller 230 prior to or after implantation of the IMD 110 into the patient'"'"'s body. The stimulation controller 230 controls the operation of the stimulation unit 250, which generates the stimulation pulses comprising a burst according to the parameters defined by the controller 230 and, in some embodiments, provides these pulses to the lead assembly 122 and electrode assembly 125. Stimulation pulses provided by the IMD 110 may vary widely across a range of parameters. The stimulation controller 230 may comprise hardware, software, firmware or any combination thereof.
In some embodiments, the stimulation logic 255 (stimulation controller 230 and stimulation unit 250) delivers stimulation bursts in response to certain events. For example, in some cases, the controller 230 and the unit 250 may deliver a stimulation burst in response to detecting an impending or already-occurring seizure based on one or more of the patient'"'"'s cardiac parameters (e.g., heart rate, rate of change of heart rate, heart rate variability, etc.). However, detection logic 270 may be implemented anywhere on the patient'"'"'s body to detect any type of event. In some embodiments, the detection logic 270 may be disposed in a location other than the patient'"'"'s body to detect some other type of event independent of the patient'"'"'s body (e.g., a request for a stimulation burst initiated by the patient). Detection logic 270 may include a sensor (e.g., a sensor that detects user input, such as a tap or magnetic input apparatus). Upon detecting an event, the detection logic 270 causes the stimulation controller 230 to activate the stimulation unit 250 in response to the detected event. One or more of the blocks 210-280 may comprise hardware, firmware, software or any combination thereof.
In the embodiment of
In
More generally, the embodiment of
In the example of
As previously explained, responsive, closed-loop bursts are delivered as a result of detecting some event. In at least some cases, this event is the detection of an impending or already-occurring seizure (e.g., detected by measuring one or more cardiac parameters). Although such an event detection is used to trigger the delivery of a closed-loop burst, the timing of such an event detection also may be used to adjust the regularly scheduled open-loop dosing. For instance, if seizures tend to occur within some threshold amount of time from the ends of off-time periods but before the next scheduled burst, the off-times'"'"' duration may be reduced, thereby causing the open-loop cycles to be delivered more frequently. In another example, if seizures tend to occur within some threshold amount of time after a stimulation burst, it may be the case that the stimulation parameters are counterproductive to at least some seizure events. Thus, stimulation parameters (e.g., frequency of the electrical pulses comprising a burst) may be adjusted so that seizures become less frequent. In other embodiments, stimulation may be suspended, reduced or discontinued altogether.
In embodiments involving closed-loop stimulation, an event (such as detection of an epileptic seizure) may be based upon an algorithm that processes a body parameter such as heart rate. Depending upon the algorithm and its triggering thresholds, event detection parameters may be undesirably stringent, and may result in undesirably low amounts of stimulation. Similarly, event detection parameters may sometimes be undesirably lax, resulting in undesirably high amounts of stimulation. Accordingly, in at least some embodiments, the IMD 110 may be programmed to include minimum and maximum stimulation constraints. The IMD 110 may compare the actual amount of stimulation (i.e. electrical charge) applied to the target tissue (based, for example, on the percentage of real time that stimulation is applied, or the amount of charge delivered to the nerve within one or more time frames, or the amount of time at which stimulation above a particular frequency is applied to the nerve) to these minimum and maximum constraints to ensure that the IMD 110 is not under-stimulating or over-stimulating the patient. In case the actual amount of stimulation falls below the minimum stimulation constraint, the event detection (i.e., algorithm) parameters may be modified (i.e., lowered) so that the actual amount of stimulation (in this case, rate of charge delivery) increases to meet or exceed the minimum stimulation constraint. Similarly, in case the actual stimulation amount exceeds the maximum stimulation constraint, the event detection parameters may be modified (i.e., increased) so that the actual amount of stimulation decreases to meet or fall below the maximum stimulation constraint. In this way, the actual amount of stimulation (on a charge and/or time basis) may be dynamically regulated into a desired and/or programmed range.
The techniques described herein may be implemented in various combinations. For example, the technique for reducing burst duration (depicted above in
At a more general level, additional techniques to compensate for reduced battery life associated with responsive, closed-loop bursts are possible when the full array of programmable parameters that define electrical stimulation therapies are considered. In the embodiment of
In addition to adjusting off-time and on-time, frequency and pulse-width may also be adjusted to compensate for the CLC delivered in an unprogrammed, closed-loop burst. For example, the pulse width for some or all of the pulses of one or more open-loop bursts that follow an unprogrammed, closed-loop burst may be reduced to recover the CLC delivered in the closed-loop burst. For example, although not depicted in the Figures, the programmed pulse width of an open-loop stimulation program for a patient may be set at 250 microseconds. Following delivery of a closed-loop burst having the same on-time, frequency, pulse width, and current settings as an open-loop burst, the pulse width of the next 5 subsequent open-loop bursts may be reduced to 200 microseconds to recover the CLC applied in the closed-loop burst. Similarly, where open-loop frequency is programmed at 30 Hz, the frequency of the next 3 open-loop bursts may be reduced to 20 Hz to recover the CLC applied during a closed-loop burst (assuming that the closed-loop burst has the same one-time, frequency, pulse width and current as a programmed open-loop burst). Finally, when open-loop bursts have a programmed current of 2 milliamperes (mA), the charge delivered in a closed-loop burst having the same program parameters as the open-loop bursts may be recovered by reducing the programmed current to 1 mA for the next two open-loop bursts following the closed-loop burst. It will also be appreciated that slightly different adjustments to on-time, off-time, frequency, pulse width and/or current may be made to recover the charged applied in a closed-loop burst having different parameters (for example, a different on-time, frequency, pulse width, and/or current) than a programmed open-loop burst.
More generally, following delivery of a responsive, closed-loop burst, one of more of the off-time, on-time, pulse width and current for one or more subsequent open loop bursts may be adjusted to maintain the same rate of electrical charge delivery (i.e., coulombs of charge per unit time) as provided in programmed, open loop stimulation with no closed-loop stimulation. In other embodiments, one or more of the on-time, pulse width, and current of the closed-loop burst may also be adjusted based upon the time following the previous programmed, open-loop burst that the closed-loop burst is initiated.
The foregoing techniques may be generally described by way of method 400 of
As previously explained herein, techniques for conserving battery life are described first, followed by a description of techniques for accurately predicting battery life. The techniques for conserving battery life having been fully described, the techniques for accurately predicting battery life now follow.
Generally, in at least some battery life prediction embodiments, an estimate of battery longevity is first made based on both an open-loop stimulation program and predicted closed-loop stimulation (based on the patient'"'"'s personal disease history, detector performance capabilities, and/or one or more of a variety of other factors). Subsequently, in such embodiments, the rate of closed-loop stimulation that is actually provided by the IMD 110 when the IMD 110 is implanted and operating inside the patient'"'"'s body (i.e., the rate of closed-loop stimulation “in real life”) is recorded and is used to adjust the estimate of battery longevity. Alternatively to the determination in step 504 of the rate at which closed-loop electrical stimulation bursts are actually applied to a cranial nerve, the IMD 110 may be programmed to deliver only open-loop therapy, but to record when closed-loop therapy would have been delivered had closed-loop therapy been enabled. This recorded information can then be used to estimate battery longevity. The estimation may be used to adjust IMD parameters in consideration of estimated battery longevity and, if desired, closed-loop stimulation may thereafter be enabled.
In some embodiments, longevity estimates of the IMD 110 (more specifically, longevity of the power source 210) may be determined by first estimating longevity based on (1) programmed, open-loop stimulation and (2) estimates of responsive, closed-loop stimulation using the patient'"'"'s personal disease history and the detection capabilities (e.g., sensitivity) of the detection logic 270. After longevity of the IMD 110 is estimated in this way, the estimate is refined by monitoring the quantity of responsive, closed-loop stimulation bursts that are delivered by the IMD 110 after the IMD 110 is implanted in the patient'"'"'s body. A log of such stimulation activity may be recorded in storage 280 and later provided to the external unit 150 via the communication unit 260. Alternatively, the log may be provided in real-time to the external unit 150 via the communication unit 260. In either case, the actual closed-loop stimulation data is used to refine the initial estimate regarding longevity of the IMD 110.
In some embodiments, a different technique may be used to refine the initial estimate regarding longevity of the IMD 110. In such embodiments, the IMD 110 is programmed to deliver not only scheduled, open-loop stimulations but is further programmed to record each instance at which the IMD 110 would have delivered an unscheduled, closed-loop stimulation had it been enabled to do so. These recorded data may be provided to the external unit 150 in real-time or may be stored in storage 280 for subsequent transfer to the external unit 150. In either case, the recorded data then are used to refine the initial estimate regarding longevity of the IMD 110.
Initial estimates and refinements thereto preferably are performed by the external unit 150 but also may be performed by the IMD 110 (e.g., by the power-source controller 220, the power regulation unit 240, stimulation logic 255 or any other suitable circuit logic). In some cases, portions of the initial estimates and/or refinements may be performed on the IMD 110 with the remainder of the estimates and/or refinements performed on the external unit 150. Both the initial estimates and refined predictions are displayed or otherwise provided to an end-user of the external unit 150 (e.g., the patient'"'"'s physician). The end-user may adjust IMD 110 closed-loop algorithm parameters (e.g., maximum and minimum stimulation thresholds at which a signal to initiate closed-loop stimulation is generated) in light of the estimated longevity. The end-user also may enable or disable responsive, closed-loop stimulations by the IMD 110.
The method 500 further comprises re-calculating the device longevity estimate based on the program parameters for open-loop stimulation and the determination of block 504 to produce a modified device longevity estimate (block 506). The method 500 may, in some embodiments, further comprise modifying the operation of the device based on the modified device longevity calculation (block 508). In the action of block 508, the refined predictions may be provided to the end-user (e.g., a physician) so that the user may take appropriate action by modifying the operation of the IMD 110 as described above. For instance, IMD 110 parameters (e.g., maximum and minimum stimulation thresholds) may be adjusted, and closed-loop stimulation may be activated or deactivated.
The above discussion is meant to be illustrative of the principles and various embodiments of the present invention. Numerous variations and modifications will become apparent to those skilled in the art once the above disclosure is fully appreciated. It is intended that the following claims be interpreted to embrace all such variations and modifications.